Prevention of Esophageal Varices by Beta-Adrenergic Blockers
Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Listed as NCT00006398, this PHASE3 trial focuses on Esophageal and Gastric Varices and Liver Cirrhosis and remains completed. Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), it has been updated 6 times since 1993, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2017 [monthly]
Completed PHASE3
First recorded
Aug 1993
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Yale University
For direct contact, visit the study record on ClinicalTrials.gov .